IPO in June, 2016 (NASDAQ:CLSD).

Manufacturer of late-stage clinical biopharmaceutical products created to offer innovative first-in-class drug therapies to treat blinding diseases. The company's late-stage clinical biopharmaceutical products provide a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork and corneal stroma through an ocular micro injection platform enabling patients suffering from sight threatening diseases such as uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration to avail potentially meaningful treatment benefit.